Message from the President and CEO

I am truly delighted that three of our researchers have been recognized for their work in opening a new chapter in the treatment of hemophilia A. I would like to express my deepest respect for their creativity and unwavering dedication in conceiving and realizing the unprecedented idea of substituting the function of coagulation Factor VIII with a bispecific antibody, overcoming numerous challenges along the way. I would also like to extend my heartfelt gratitude to the people with hemophilia A and their families who participated in clinical trials, to healthcare professionals including those at Nara Medical University who provided outstanding expertise in hemophilia research and clinical practice while collaborating with us in advancing research, and to all those involved in the journey from research and development to manufacturing, regulatory approval, and commercialization.

For many years, people with hemophilia A faced significant medical challenges, including the burden of administering intravenous injections at home multiple times a week and the development of Factor VIII inhibitors, which could limit subsequent treatment options. There was a need for a treatment that would reduce this burden while providing sustained and reliable bleed prevention. Administered subcutaneously as infrequently as once every one to four weeks*, emicizumab has reduced treatment burden while lowering annualized bleeding rates regardless of the presence or absence of Factor VIII inhibitors. In doing so, it has helped bring a new daily life to people with hemophilia A and their families.

The development of medicines requires many years. From the initial concept to realization, emicizumab's journey spanned 17 years and involved overcoming countless challenges, including the screening of a vast number of antibodies and the development of proprietary antibody engineering technologies that enabled commercial-scale manufacturing. Since our founding, Chugai has been guided by the aspiration to “create drugs that benefit the world” and by a pioneering spirit that drives us to tackle unprecedented challenges. The story of emicizumab, from its creation to its delivery to people around the world, embodies these values. What makes such groundbreaking achievements possible is an environment that empowers every employee to take bold challenges driven by their commitment to patients, together with a culture that believes in individual potential and actively supports those challenges. We believe that the accumulation of such efforts is what creates entirely new value for society.

Moreover, the journey of translating this research achievement into a product called Hemlibra and delivering it to people with hemophilia A around the world was not achieved by Chugai alone. Under the strategic alliance established with Roche in 2002, Roche, Genentech, and Chugai combined their respective strengths to advance global

CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.
1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo 103-8324 Japan
Media Relations Group TEL: +81-(0)3-3273-0881 E-mail: pr@chugai-pharm.co.jp
Investor Relations Group TEL: +81-(0)3-3273-0554 E-mail: ir@chugai-pharm.co.jp

development, regulatory submissions, and commercialization. As a result, emicizumab is now approved in more than 120 countries and territories, and more than 30,000 people with hemophilia A worldwide have been treated with emicizumab to date (cumulative global total as of the end of June 2026).

Looking ahead, we will continue to create innovative drugs and services through our unique science and technologies, working in collaboration with partners around the world. We hope that this recognition of our three researchers will inspire all those who are pursuing bold ambitions globally and encourage them to help shape a better future.

*Excerpt from the electronic package insert information *Relevant sections only

4. Indications

- For routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital hemophilia A (congenital factor VIII deficiency).

6. Dosage and Administration

<For routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital hemophilia A (congenital factor VIII deficiency)>

- Administer emicizumab (genetically engineered) by subcutaneous injection at a dose of 3 mg/kg once weekly for the first 4 weeks. One week after the fourth dose (Week 5 from the initial dose), administer one of the following maintenance regimens by subcutaneous injection:
- 1.5 mg/kg once every week
- 3 mg/kg once every two weeks
- 6 mg/kg once every four weeks